Diametric Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Diametric Capital’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,423	Closed	-$47.1K	–	336
2025 Q1	$47.1K	Buy	+12,423	New	+$71K	0.06%	191

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Diametric Capital's DMAC Position: Q2 2025 in Review

Diametric Capital sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 12,423 shares — an estimated $47.1K sold.

Diametric Capital first reported a position in DMAC in Q1 2025 and held it in 1 quarter. The position peaked at $47.1K in Q1 2025. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

Diametric Capital reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
Diametric Capital sold 12,423 DiaMedica Therapeutics shares in Q2 2025, an estimated $47.1K.
Diametric Capital first reported a position in DiaMedica Therapeutics in Q1 2025 and held it in 1 quarter.
Diametric Capital's DiaMedica Therapeutics position peaked at $47.1K in Q1 2025.
58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.